Uncategorized

Marjorie Taylor Greene slams FDA green lighting of mNEXSPIKE COVID-19 vaccine: ‘Not MAHA at all!!!’

Rep. Marjorie Taylor Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine, describing the move as "Not MAHA at all!!!' in a post on X

Rep. Marjorie Taylor Greene, R-Ga., slammed the U.S. Food and Drug Administration’s move to give the green light to Moderna’s mNEXSPIKE COVID-19 vaccine.

“Not MAHA at all!!!,” the congresswoman wrote in a post on X, using the acronym for the phrase “Make America Healthy Again,” calling the move “Unreal.”

“MNEXSPIKE is approved for use in individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19,” an FDA letter to Moderna notes.


GREENE CALLS FOR YANKING FDA APPROVAL OF COVID-19 VACCINES: ‘CAUSING PERMANENT HARM AND DEATHS’

According to a Moderna press release, CEO Stéphane Bancel said that “COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone.”

The company describes itself as “a leader in the creation of the field of mRNA medicine.”

REP. MARJORIE TAYLOR GREENE AIRS FRUSTRATIONS, WARNS THAT SHE REPRESENTS A ‘NOT HAPPY’ REPUBLICAN BASE

Greene has previously spoken out against COVID-19 vaccines, saying their FDA approval should be nixed.

“COVID-19 vaccines should have never received approval and they’ve known the entire time how bad the side effects are and deaths caused by them. It’s time to do the right thing. Stop the COVID-19 vaccines,” she declared in part of a tweet in March.

See also  Walmart Hit with Civil Penalties After Shipping Toy Gun to Liberal State

TRUMP ALLY MARJORIE TAYLOR GREENE SAYS SHE WON’T RUN FOR SENATE WHILE BLASTING DEMS AND FELLOW REPUBLICANS

The congresswoman is currently serving her third term in the House of Representatives.

Share this article:
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter